MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $393.04 million. The enterprise value is $250.76 million.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 105.35 million shares outstanding. The number of shares has increased by 1.53% in one year.
| Current Share Class | 105.35M |
| Shares Outstanding | 105.35M |
| Shares Change (YoY) | +1.53% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 96.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 10.46 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.31, with a Debt / Equity ratio of 0.08.
| Current Ratio | 14.31 |
| Quick Ratio | 13.19 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.33% and return on invested capital (ROIC) is -11.64%.
| Return on Equity (ROE) | -15.33% |
| Return on Assets (ROA) | -11.07% |
| Return on Capital (ROIC) | -11.64% |
| Revenue Per Employee | $317,755 |
| Profits Per Employee | -$247,762 |
| Employee Count | 143 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.94% in the last 52 weeks. The beta is 1.13, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +9.94% |
| 50-Day Moving Average | 3.89 |
| 200-Day Moving Average | 4.28 |
| Relative Strength Index (RSI) | 49.68 |
| Average Volume (20 Days) | 274,738 |
Short Selling Information
The latest short interest is 3.51 million, so 3.33% of the outstanding shares have been sold short.
| Short Interest | 3.51M |
| Short Previous Month | 3.85M |
| Short % of Shares Out | 3.33% |
| Short % of Float | 3.64% |
| Short Ratio (days to cover) | 10.27 |
Income Statement
In the last 12 months, MaxCyte had revenue of $45.44 million and -$35.43 million in losses. Loss per share was -$0.34.
| Revenue | 45.44M |
| Gross Profit | 40.18M |
| Operating Income | -46.29M |
| Pretax Income | -35.43M |
| Net Income | -35.43M |
| EBITDA | -41.92M |
| EBIT | -46.29M |
| Loss Per Share | -$0.34 |
Full Income StatementBalance Sheet
The company has $157.33 million in cash and $18.53 million in debt, giving a net cash position of $138.80 million or $1.32 per share.
| Cash & Cash Equivalents | 157.33M |
| Total Debt | 18.53M |
| Net Cash | 138.80M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 221.26M |
| Book Value Per Share | 2.11 |
| Working Capital | 163.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.66 million and capital expenditures -$2.73 million, giving a free cash flow of -$25.39 million.
| Operating Cash Flow | -22.66M |
| Capital Expenditures | -2.73M |
| Free Cash Flow | -25.39M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
Gross margin is 88.43%, with operating and profit margins of -101.88% and -77.97%.
| Gross Margin | 88.43% |
| Operating Margin | -101.88% |
| Pretax Margin | -77.97% |
| Profit Margin | -77.97% |
| EBITDA Margin | -92.25% |
| EBIT Margin | -101.88% |
| FCF Margin | -55.87% |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.53% |
| Shareholder Yield | -1.53% |
| Earnings Yield | -9.01% |
| FCF Yield | -6.46% |
Analyst Forecast
The average price target for MaxCyte is $8.67, which is 130.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 130.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 28.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 7.97 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.97 |
| Piotroski F-Score | 3 |